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Introduction: The different distribution of T cells among activation/differentiation stages in immune disorders may
condition the outcome of mesenchymal stromal cell (MSC)-based therapies. Indeed, the effect of MSCs in the
different functional compartments of T cells is not completely elucidated.
Methods: We investigated the effect of human bone marrow MSCs on naturally occurring peripheral blood
functional compartments of CD4+ and CD8+ T cells: naive, central memory, effector memory, and effector
compartments. For that, mononuclear cells (MNCs) stimulated with phorbol myristate acetate (PMA) plus ionomycin
were cultured in the absence/presence of MSCs. The percentage of cells expressing tumor necrosis factor-alpha
(TNF-α), interferon gamma (IFNγ), and interleukin-2 (IL-2), IL-17, IL-9, and IL-6 and the amount of cytokine produced
were assessed by flow cytometry. mRNA levels of IL-4, IL-10, transforming growth factor-beta (TGF-β), and cytotoxic
T-lymphocyte-associated protein 4 (CTLA4) in purified CD4+ and CD8+ T cells, and phenotypic and mRNA
expression changes induced by PMA + ionomycin stimulation in MSCs, were also evaluated.
Results: MSCs induced the reduction of the percentage of CD4+ and CD8+ T cells producing TNF-α, IFNγ, and IL-2
in all functional compartments, except for naive IFNγ+CD4+ T cells. This inhibitory effect differentially affected CD4+
and CD8+ T cells as well as the T-cell functional compartments; remarkably, different cytokines showed distinct
patterns of inhibition regarding both the percentage of producing cells and the amount of cytokine produced.
Likewise, the percentages of IL-17+, IL-17+TNF-α+, and IL-9+ within CD4+ and CD8+ T cells and of IL-6+CD4+ T cells
were decreased in MNC-MSC co-cultures. MSCs decreased IL-10 and increased IL-4 mRNA expression in stimulated
CD4+ and CD8+ T cells, whereas TGF-β was reduced in CD8+ and augmented in CD4+ T cells, with no changes for
CTLA4. Finally, PMA + ionomycin stimulation did not induce significant alterations on MSCs phenotype but did increase
indoleamine-2,3-dioxygenase (IDO), inducible costimulatory ligand (ICOSL), IL-1β, IL-8, and TNF-α mRNA expression.
Conclusions: Overall, our study showed that MSCs differentially regulate the functional compartments of CD4+ and
CD8+ T cells, which may differentially impact their therapeutic effect in immune disorders. Furthermore, the influence
of MSCs on IL-9 expression can open new possibilities for MSC-based therapy in allergic diseases.* Correspondence: artur.paiva@ipst.min-saude.pt
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The discovery of the immunosuppressive potential of
mesenchymal stromal cells (MSCs) propelled a large num-
ber of studies in the past decade, mainly focusing on T
cells. The suppressive effect of MSCs over T cells com-
prises inhibition of T-cell proliferation, activation, differ-
entiation in effector cells, and effector function by altering
their cytokine profile and impairing the cytolytic activity
of cytotoxic T cells [1]. MSC-derived immunosuppression
can be achieved by direct MSC-T cell interaction, through
plasmatic membrane proteins or soluble factors produced
by MSCs, or indirectly by MSC-mediated suppression of
antigen-presenting cells [2]. In fact, human bone marrow
(BM) MSCs impair dendritic cell maturation and de-
crease the expression of co-stimulatory molecules and
interleukin-12 (IL-12) while increasing IL-10 expression
and consequently hampering T-cell activation [2-6]. A
similar effect is observed in monocytes which, in the pres-
ence of human BM-MSCs, develop an anti-inflammatory
phenotype with increased IL-10 expression [7-9].
However, it is well established that the behavior of
MSCs depends on numerous factors, such as the source
of MSCs, the type of immune cells present in the cell
culture, the state of activation and differentiation of the
T cells, and the type of stimuli used [10-14]. In turn, the
information available on the effect of MSCs over T cells
at different stages of activation/differentiation is scarce,
and the data concerning the influence of MSCs on the
naive-effector T-cell differentiation process are contra-
dictory. Most of the publications describe an inhibitory
action over Th1 and Th17 differentiation, along with a
decreased expression of the cytokines related to these
effector phenotypes—interferon gamma (IFNγ), IL-2,
and tumor necrosis factor-alpha (TNF-α) for Th1; and
IL-17A, IL-17F, and IL-21 for Th17—both in vitro and
in vivo [1,14-19]. Nevertheless, some studies reported
that MSCs promote Th17 differentiation and IL-17A
production [1,20-23].
Different disorders of the immune system and differ-
ent stages of each immune disease are characterized by
distinctive distribution of T cells among activation/dif-
ferentiation compartments, which is a reflection of the
T-cell subsets with a predominant role in the disease
etiology. This highlights the importance of knowing the
effect of MSCs on each individual functional compart-
ment in order to predict and understand the outcome
of MSC cell therapy.
Here, we investigate the suppressive effect of human
BM-MSCs over peripheral blood CD4+ and CD8+ T cells
distributed among the naturally occurring naive, central
memory (CM), effector memory (EM), and effector com-
partments. Peripheral blood mononuclear cells (MNCs)
were stimulated with phorbol myristate acetate (PMA)
plus ionomycin in the absence/presence of MSCs, andthe expression of IL-2, TNF-α, and IFNγ was evaluated
by flow cytometry for CD4+ and CD8+ T cells distributed
among the naive, CM, EM, and effector compartments;
the expression of IL-6, IL-9, and IL-17 was also evalu-
ated in total CD4+ and CD8+ T cells. In addition, IL-4,
IL-10, transforming growth factor-beta (TGF-β), and
T-lymphocyte-associated protein 4 (CTLA4) mRNA
levels were assessed in fluorescence-activated cell sort-
ing (FACS)-purified CD4+ and CD8+ T cells. Finally,
the protein expression of CD13, CD44, CD73, CD90,
CD106, and CD184 (CXCR4) and mRNA transcripts of
indoleamine-2,3-dioxygenase (IDO), inducible costimula-
tory ligand (ICOSL), TGF-β1, IL-1β, IL-8, and TNF-α
were evaluated in non-stimulated MSCs and after stimula-
tion with PMA plus ionomycin.
In this study, we report that the functional compart-
ments of CD4+ and CD8+ T cells are differentially regu-
lated by MSCs, which may condition the outcome of
MSC cell therapy in immune disorders with distinctive
distribution of T cells among activation/differentiation
compartments. Of note, MSCs decrease the percentage
of CD4+ and CD8+ T cells expressing TNF-α, IFNγ, IL-2,
IL-6, IL-9, and IL-17 as well as the amount of TNF-α
and IFNγ produced at a single-cell level. The influence
of MSCs on IL-9 can be a possible mechanism contrib-
uting to allergic inflammation amelioration by MSCs.
Materials and methods
Collection and isolation of peripheral blood mononuclear
cells and bone marrow mesenchymal stromal cells
Peripheral blood samples from a total of eight healthy
donors (one male and seven females; mean age of 41 ±
11 years, ranging from 21 to 50 years old), collected in
heparin at the Blood and Transplantation Center of
Coimbra (Portugal), and human BM samples from healthy
donors (age ranging from 20 to 40 years old) were in-
cluded in the present study. The use of these biological
samples for research purpose was approved by the ethics
committee of Instituto Português de Oncologia de Lisboa
Francisco Gentil (laws 97/95 and 46/2004), and all partici-
pants gave written informed consent before entering in
the study.
Peripheral blood MNCs were isolated by Lymphoprep
(Stemcell Technologies, Vancouver, BC, Canada) gradient
density centrifugation and then washed twice in Hank’s
Balanced Salt Solution (Gibco, Life Technologies, Paisley,
UK). The MNCs pellet was resuspended in RPMI 1640
with GlutaMax medium (Invitrogen, Life Technologies)
with antibiotic-antimycotic (Gibco) to the final concentra-
tion of 106 cells/mL.
Peripheral blood MNCs were subsequently analyzed
for protein and mRNA expression in the following experi-
mental conditions: (1) 0.5 × 106 MNCs + 500 μL RPMI
(negative control), (2) 0.5 × 106 MNCs + 0.25 × 106 MSCs
Laranjeira et al. Stem Cell Research & Therapy 2015, 6:3 Page 3 of 14
http://stemcellres.com/content/6/1/3(negative control), (3) 0.5 × 106 MNCs + 500 μL RPMI +
PMA+ ionomycin (positive control), and (4) 0.5 × 106
MNCs + 0.25 × 106 MSCs + PMA+ ionomycin. All of the
aforementioned cell cultures were carried out for 20 hours
at 37°C, in a sterile environment with 5% CO2 and hu-
midified atmosphere, plus an incubation period of 4 hours
with the stimulator agents. The cell culture and stimula-
tion protocols are detailed below in the “Immunophenoty-
pic study of mesenchymal stromal cells and peripheral
blood T cells” section.
For the isolation of human BM-MSCs, MNCs were
isolated from BM samples by using a Sepax S-100
system (Biosafe, Eysins, Switzerland) in accordance with
the instructions of the manufacturer. Cell number and
viability were determined using the Trypan Blue (Gibco)
exclusion method.
BM MNCs were plated at a density of 2 × 105 cells/cm2
in Dulbecco’s modified Eagle’s medium (Gibco) supple-
mented with 10% qualified fetal bovine serum (Sigma-
Aldrich). After a 3-day incubation at 37°C in humidified
atmosphere containing 5% CO2, the non-adherent cell
fraction was discarded, and the adherent culture was main-
tained with a complete medium renewal every 3 to 4 days.
After reaching a 70% to 80% confluency cells were de-
tached by using TrypLE (Life Technologies) for 7 minutes
and then replated at an initial density of 3,000 cells/cm2.
For this study, MSCs passages 3 and 5 were used.
MSCs identity was confirmed by performing fluores-
cent morphological analysis, mesodermal differentia-
tion assays (osteogenic, adipogenic, and chondrogenic),
and immunophenotype characterization as described by
Dominici et al. [24]. Subsequently, MSCs were resuspen-
ded in RPMI 1640 with GlutaMax medium (Invitrogen)
with antibiotic-antimycotic (Gibco) to the final concentra-
tion of 0.5 × 106 cells/mL. The protein and mRNA expres-
sion of MSCs was studied in the following experimental
conditions: (1) 0.25 × 106 MSCs + 500 μL RPMI (non-
stimulated MSCs) and (2) 0.25 × 106 MSCs + 500 μL
RPMI + PMA+ ionomycin. All of the aforementioned cell
cultures were carried out for 20 hours at 37°C, in a sterile
environment with 5% CO2 and humidified atmosphere,
plus an incubation period of 4 hours with the stimulator
agents. The cell culture and stimulation protocols are de-
tailed below, in “Immunophenotypic study of mesenchy-
mal stromal cells and peripheral blood T cells” section.
Immunophenotypic study of mesenchymal stromal cells
and peripheral blood T cells
Mesenchymal stromal cell stimulation with phorbol
myristate acetate plus ionomycin
For the immunophenotypic study of MSCs, we plated
in four wells of tissue culture plates (Falcon, Becton
Dickinson Biosciences, BD, San Jose, CA, USA) 0.25 × 106
MSCs in 1 mL of RPMI 1640 with GlutaMax medium(Invitrogen) with antibiotic-antimycotic (Gibco). MSCs
were cultured for 20 hours at 37°C in a sterile environ-
ment with 5% CO2 and humidified atmosphere (to be
in the same experimental conditions than as those MSCs
co-cultured with MNCs). MSCs from two of the four
wells were stimulated with PMA (50 ng/mL; Sigma-
Aldrich) plus ionomycin (1 μg/mL; Boehringer Mannheim,
Germany) for 4 hours at 37°C in humidified atmos-
phere containing 5% CO2; in the remaining two wells,
MSCs were not stimulated. The immunophenotypic
study and mRNA expression quantification were per-
formed in non-stimulated and PMA + ionomycin-stim-
ulated MSCs.
Immunophenotypic study of mesenchymal stromal cells
For each experimental condition tested, cells were
detached by using TrypLE (Gibco); after incubating for
10 minutes at −20°C, the content of each well was
transferred to a 12 × 75 mm polystyrene cytometer
tube, centrifuged for 5 minutes at 540 g and the super-
natant was discarded. MSCs immunophenotype was
assessed by using the seven-color monoclonal antibody
(mAb) combination detailed in Table 1, tube 1. The cell
pellet was incubated with the mAb for 10 minutes in
the darkness and washed with phosphate-buffered sa-
line (PBS). Finally, cells were resuspended in 500 μL of
PBS and immediately acquired in a FACSCanto II (BD)
flow cytometer.
Co-culture of peripheral blood mononuclear cells and
mesenchymal stromal cells and in vitro stimulation with
phorbol myristate acetate plus ionomycin
In four wells of tissue culture plates (Falcon), 0.5 × 106
MNCs were plated in 1 mL of RPMI 1640 with Gluta-
Max medium (Invitrogen) with antibiotic-antimycotic
(Gibco), and in four other wells of tissue culture plates
(Falcon), we plated 0.5 × 106 MNCs + 0.25 × 106 MSCs
in a final volume of 1 mL, establishing a ratio of 2:1
(MNCs:MSCs). Cells were cultured for 20 hours at 37°C
in a sterile environment with 5% CO2 and humidified
atmosphere.
After the incubation period, PMA+ ionomycin (50 ng/mL
and 1 μg/mL, respectively) was added to two wells with
MNCs and two wells with co-cultured MNCs +MSCs;
the cells in the remaining wells (two with MNCs and
two with MNCs +MSCs) were not stimulated. Brefeldin
A (10 μg/mL) from Penicillium brefeldiamun (Sigma-
Aldrich) was added to one well of each experimental
condition—(1) MNCs, (2) MNCs +MSCs, (3) MNCs +
PMA+ ionomycin, and (4) MNCs +MSCs + PMA+ iono-
mycin—to prevent the release of de novo produced cyto-
kines outside the cells. We proceeded to an incubation at
37°C in a sterile environment with 5% CO2 humidified
atmosphere for 4 hours.
Table 1 Panel of monoclonal antibody reagents (with clones and commercial source) used for the immunophenotypic
characterization of mesenchymal stromal cells and peripheral blood T cells
Fluorochrome
Tube PacB PacO FITC PE PerCPCy5.5
or PECy5
PECy7 APC APCH7
























HI100 BD SK1 BD











HI100 BD SK1 BD
4 CD3 cyIL-2 cyIL-9 CD27 CD4 CD45RA CD8
UCHT1 BD
Pharmingen






HI100 BD SK1 BD













Commercial sources: Biolegend (San Diego, CA, USA), Invitrogen, Life Technologies (Carlsbad, CA, USA), BD Pharmingen (San Diego, CA, USA), BD (Becton Dickinson
Biosciences, San Jose, CA, USA), Beckman Coulter (Miami, FL, USA). APC, allophycocyanin; APCH7, allophycocyanin-hilite 7; FITC, fluorescein isothiocyanate; mAb,
monoclonal antibody; MSC, mesenchymal stromal cell; PacB, pacific blue; PacO, pacific orange; PE, phycoerythrin; PECy5, phycoerythrin-cyanine 5; PECy7,
phycoerythrin-cyanine 7; PerCPCy5.5, peridinin chlorophyll protein-cyanine 5.5.
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of cytokine expression in T cells by flow cytometry, while
the mRNA expression was performed in the samples
without brefeldin A. All of the aforementioned protein
and mRNA expression studies were performed in all of
the different culture conditions: MNCs, MNCs +MSCs,
MNCs + PMA+ ionomycin, and MNCs +MSCs + PMA+
ionomycin.
Immunophenotypic study of peripheral blood T cells
For each experimental condition tested, cells were
detached by using TrypLE (Gibco); after incubating for
10 minutes at −20°C, the content of each well was trans-
ferred to a 12 × 75 mm polystyrene cytometer tube,
centrifugedv for 5 minutes at 540 g and the supernatant
was discarded. Immunophenotypic analysis of peripheral
blood T cells, cultured in the presence/absence of PMA +
ionomycin and in the presence/absence of MSCs, was
performed by using seven-color mAb combinations,
detailed in Table 1. In short, cells were stained with the
mAb for surface proteins antigens (CD3, CD27, CD4,
CD45RA, and CD8) and, after an incubation period of
10 minutes in the dark at room temperature, washed
with PBS. For intracellular staining, Fix&Perm (Caltag,
Hamburg, Germany) reagent was used, in accordance
with the instructions of the manufacturer and in paral-
lel with the mAb for TNF-α and IL-17 (tube 2), IFNγ
and IL-6 (tube 3), or IL-2 and IL-9 (tube 4). After
washing twice with PBS, the cell pellet was resuspended
in 500 μL of PBS and immediately acquired.Data acquisition and analysis
Data acquisition were performed in a FACSCanto™II (BD)
flow cytometer equipped with FACSDiva software (version
6.1.2; BD). For both MSCs and MNCs immunophenotypic
studies, the whole sample from each tube was acquired
and stored, corresponding to a number of events always
above 0.1 × 106 or 0.5 × 106 events, respectively. For data
analysis, Infinicyt (version 1.7) software (Cytognos SL,
Salamanca, Spain) was used.
Immunophenotypic identification of T cells within the
different functional compartments
The identification and quantification of the four T-cell
functional compartments were carried out after the ex-
clusion of cell debris (which corresponded to events with
very low forward scatter (FSC) and heterogeneous side
scatter (SSC) light dispersion properties) and doublets
(identified by their FSC area and FSC height charac-
teristics). T cells were identified on the basis of CD3
positivity and intermediate FSC and SSC properties
(Additional file 1: Figure S1). Within this cell popula-
tion, the functional compartments of CD4+ and CD8+
T cells (phenotypically characterized as CD3+CD4+CD8−
and CD3+CD4−CD8+, respectively) were identified accord-
ing to their differential expression of CD45RA and CD27
as follows: naive T cells are characterized by CD45RA+
CD27+ expression, CM T cells are CD45RA−CD27+,
and EM and effector T cells display CD45RA−CD27−
and CD45RA+CD27− immunophenotype, respectively
(Additional file 1: Figure S1).
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CD4+ and CD8+ T-cell populations from the cell cultures
were purified by FACS (using a FACSAria II flow cytometer;
BD) according to their typical phenotype. Thus, the six-color
mAb combination used (Table 1, tube 5) allowed the iden-
tification of CD4+ T cells (CD3+CD4+CD8−TCRγδ−) and
CD8+ T cells (CD3+CD4−CD8+TCRγδ−). The remaining
mAbs found in the panel were used to exclude γδ T cells
(which correspond to CD3+TCRγδ+ events) and regula-
tory T (Treg) cells (which are CD25++CD127−/dim). The
purified cell populations were subsequently used for the
quantification of mRNA expression.Analysis of mRNA expression in mesenchymal stromal
cells and purified CD4+ and CD8+ T cells
The content of each well of cultured MSCs under the
different experimental condition tested, or the purified
CD4+ and CD8+ T-cell populations, were transferred to
a 1.5-mL Eppendorf tube and centrifuged for 5 minutes
at 300 g, and the pellet was resuspended in 350 μL of
RLT Lysis Buffer (Qiagen, Hilden, Germany). Total RNA
was extracted with the RNeasy Micro kit (Qiagen) in ac-
cordance with the instructions of the supplier. Total
RNA was eluted in a 20-μL volume of RNase-free water.
RNA was reverse-transcribed with Tetra cDNA Syn-
thesis (Bioline, London, UK) in accordance with the in-
structions of the manufacturer. Relative quantification of
gene expression by real-time polymerase chain reaction
(PCR) was performed in the LightCycler 480 II (Roche
Diagnostics, Rotkreuz, Switzerland). Real-time PCRs
were carried out by using 1x QuantiTect SYBR Green
PCR Master Mix (Qiagen) and 1x QuantiTect Primer
Assay (for MSCs: TNF3: QT01079561; IL-8: QT00000322;
IL-1β: QT00021385; TGF-β1: QT00025718; ICOSL:
QT00023660; IDO: QT00000504; for purified CD4+ and
CD8+ T cells: IL-10: QT00041685; IL-2: QT00015435;
IL-4: QT00012565; TGF-β: QT00000728; CTLA4: QT
01670550) (Qiagen) in a final volume of 10 μL. The re-
actions were performed by using the following thermal
profile: one cycle of 10 minutes at 95°C, 50 cycles of
10 seconds at 95°C, 20 seconds at 55°C and 30 seconds
at 72°C, one cycle of 5 seconds at 95°C, 1 minute at 65°C
and continuo at 97°C, and one cycle of 10 seconds at
21°C. All samples were run in duplicate. Real-time PCR
results were analyzed with the LightCycler software
(Roche Diagnostics). GeNorm software (PrimerDesign
Ltd., Southampton, UK) was used to select the reference
genes to normalize data. The reference genes used for
gene expression analysis were cytochrome c1 (CYC1) and
splicing factor 3a subunit 1 (SF3A1) for MSCs and beta-2
microglobulin (B2M) and tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta
(YWHAZ) for CD4+ and CD8+ T cells. The normalizedexpression levels of the genes of interest were calculated
by using the delta Ct (change in threshold cycle) method.
Statistical analysis
To determine the statistic significance of the differences
observed between different culture conditions, non-
parametric Wilcoxon and Friedman’s paired-sample
tests were performed by using Statistical Package for
Social Sciences (IBM SPSS, version 17.0; IBM Corporation,
Armonk, NY, USA). Data were expressed as mean per-
centage ± standard deviation. Statistically significant dif-
ferences were considered when the P value was lower
than 0.05.
Results
To investigate the ability of MSCs to regulate cytokine
protein expression in CD4+ and CD8+ T cells and how
the influence of MSCs varies among the different T-cell
functional compartments (naive, CM, EM, and effector
compartment), non-stimulated or PMA + ionomycin-
stimulated MNCs were cultured in the absence or pres-
ence of MSCs. We used eight-color flow cytometry to
identify the four abovementioned compartments among
CD4+ and CD8+ T cells and analyze the protein expres-
sion of TNF-α, IFNγ, and IL-2 within each cell compart-
ment and of IL-17, IL-6, and IL-9 in total CD4+ or CD8+
T cells or both. Besides, mRNA expression of IL-4,
IL-10, TGF-β, and CTLA4 in purified CD4+ and CD8+ T
cells was also assessed. Finally, MSCs were stimulated
with PMA plus ionomycin, and the protein expression of
CD13, CD44, CD73, CD90, CD106, and CD184 (CXCR4)
and mRNA levels of IDO, ICOSL, TGF-β, IL-1β, IL-8, and
TNF-α were evaluated and compared with that of non-
stimulated MSCs.
Mesenchymal stromal cells decrease the frequency of
T cells producing TNF-α, IFNγ, and IL-2 as well as the
protein expression at single-cell level and regulate
differentially the distinct T-cell functional compartments
Co-culture of MSCs with PMA + ionomycin-stimulated
MNCs decreased the percentage of both CD4+ and CD8+
T cells expressing TNF-α (P <0.05)—observed in all indi-
viduals enrolled in this study—as well as the amount of
protein produced per cell (P <0.05), measured as mean
fluorescence intensity (MFI), in all cell compartments ana-
lyzed, except for TNF-α MFI in naive CD4+ T cells, where
MSCs did not induce changes (Figure 1). Of note, the
effect of MSCs over the frequency of TNF-α+ cells was
more pronounced in CD4+ T cells, compared with CD8+
T cells, and in naive and CM compartments for both
CD4+ and CD8+ T cells (Figure 1).
Concerning IFNγ and IL-2, we observed an overall
reduction of the frequency of both CD4+ and CD8+
T cells producing these cytokines in MSCs +MNCs +
Figure 1 Percentage of CD4+ and CD8+ T cells expressing tumor necrosis factor-alpha (TNF-α). The upper panels show the percentage
(mean ± standard deviation) of CD4+ and CD8+ T cells, distributed among their functional compartments, producing TNF-α (within the correspondent
functional compartment of CD4+ or CD8+ T cells, respectively) and amount of protein expressed per cell, measured as mean fluorescence intensity
(MFI) (mean ± standard deviation), after mononuclear cell (MNC) stimulation with phorbol myristate acetate (PMA) plus ionomycin in the absence
of mesenchymal stromal cells (MSCs) (MNCs + PMA + ionomycin) or in co-culture with MSCs (MSCs +MNCs + PMA + ionomycin). The lower panel
represents the percentage of inhibition induced by MSCs on the percentage of CD4+ and CD8+ T cells expressing TNF-α. Statistically significant
differences were considered when P <0.05 for Wilcoxon paired-sample test: *versus MSCs +MNCs + PMA+ ionomycin; **P <0.05 for the groups
indicated in the figure. CM, central memory; EM, effector memory.
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compartments of CD8+ T cells producing IFNγ and for
effector CD4+ T cells producing IL-2), as illustrated in
Figures 2 and 3. Of note, MSCs decreased the percentage
of IFNγ-producing CD4+ and CD8+ T cells in 63% and88% of the individuals under study, respectively, and in
75% and 63% of the individuals for CD4+ and CD8+ T
cells expressing IL-2, respectively. This decrease affected
all T-cell compartments but was less pronounced in naive
T cells and not visible for naive CD4+ T cells producing
Figure 2 Percentage of CD4+ and CD8+ T cells expressing interferon gamma (IFNγ). The upper panels show the percentage (mean ± standard
deviation) of CD4+ and CD8+ T cells, distributed among their functional compartments, producing IFNγ (within the correspondent functional
compartment of CD4+ or CD8+ T cells, respectively) and amount of protein expressed per cell, measured as mean fluorescence intensity (MFI)
(mean ± standard deviation), after mononuclear cell (MNC) stimulation with phorbol myristate acetate (PMA) plus ionomycin in the absence of
mesenchymal stromal cells (MSCs) (MNCs + PMA + ionomycin) or in co-culture with MSCs (MSCs + MNCs + PMA + ionomycin). The lower panel
represents the percentage of inhibition induced by MSCs on the percentage of CD4+ and CD8+ T cells expressing IFNγ. Statistically significant
differences were considered when P <0.05 for Wilcoxon paired-sample test: *versus MSCs + MNCs + PMA + ionomycin; **P <0.05 for the groups
indicated in the figure. CM, central memory; EM, effector memory.
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IFNγ produced by Tcells (measured as MFI), primarily in
EM and effector compartments (P <0.05 for EM CD4+ T
cells, EM CD8+ T cells, and effector CD8+ T cells); theeffect was more pronounced among CD8+ than CD4+ T
cells (Figure 2). In turn, concerning the amount of IL-2
produced, effector CD4+ T cells from MSCs +MNCs +
PMA + ionomycin co-cultures displayed a lower IL-2
Figure 3 Percentage of CD4+ and CD8+ T cells expressing interleukin-2 (IL-2). The upper panels show the percentage (mean ±
standard deviation) of CD4+ and CD8+ T cells, distributed among their functional compartments, producing IL-2 (within the correspondent
functional compartment of CD4+ or CD8+ T cells, respectively) and amount of protein expressed per cell, measured as mean fluorescence
intensity (MFI) (mean ± standard deviation), after mononuclear cell (MNC) stimulation with phorbol myristate acetate (PMA) plus ionomycin
in the absence of mesenchymal stromal cells (MSCs) (MNCs + PMA + ionomycin) or in co-culture with MSCs (MSCs + MNCs + PMA +
ionomycin). The lower panel represents the percentage of inhibition induced by MSCs on the percentage of CD4+ and CD8+ T cells
expressing IL-2. Statistically significant differences were considered when P <0.05 for Wilcoxon paired-sample test: *versus MSCs + MNCs +
PMA + ionomycin; **P <0.05 for the groups indicated in the figure. CM, central memory; EM, effector memory.
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(P <0.05), whereas no differences were found in the
remaining T-cell compartments (Figure 3).We observed no cytokine production by CD4+ nor CD8+
T cells in non-stimulated MNCs and non-stimulated
MNCs +MSCs cultures.
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cells producing IL-17, IL-6, and IL-9
The presence of MSCs in the stimulated-MNC culture
resulted in a decreased percentage of both Th17 and
Tc17 cells (P <0.05), verified in all individuals studied,
without alteration of the amount of IL-17 produced per
cell, measured as MFI (Figure 4). Similarly, MSCs reduced
the frequency IL-17+TNF-α+CD4+ and IL-17+TNF-α+
CD8+ T cells (P <0.05), which was observed in all indi-
viduals under study. In these T-cell populations, IL-17
MFI remained constant, whereas a lower TNF-α MFI
was detected in both cell populations for MSCs +MNCs +
PMA+ ionomycin co-cultures (P <0.05 for CD8+ T cells;
Figure 4).
The frequency of CD4+ and CD8+ T cells expressing
IL-6 or IL-9 was lower in the presence of MSCs (P <0.05
for IL-9+CD4+ T cells and IL-9+ CD8+ T cells); 88% of
individuals showed a decreased percentage of CD4+ T
cells expressing IL-6, while in 75% and 100% of the indi-
viduals, MSCs reduced CD4+ and CD8+ T cells produ-
cing IL-9, respectively (Figure 5).
We observed no cytokine production by CD4+ or CD8+
T cells in non-stimulated MNCs and non-stimulated
MNCs +MSCs cultures.mRNA expression of IL-4, IL-10, TGF-β, and CTLA4 in
purified CD4+ and CD8+ T cells from MNCs cultured in the
absence/presence of mesenchymal stromal cells
Overall, MSCs decreased IL-10 and increased IL-4
mRNA expression in stimulated CD4+ and CD8+ T cells,
while TGF-β mRNA levels were reduced in CD8+ and
augmented in CD4+ T cells, and CTLA4 remained con-
stant regardless of MSCs presence in the MNCs culture
(Figure 6). Of note, a high inter-individual variability in
mRNA levels of all molecules studied was observed.Protein and mRNA expression in phorbol myristate
acetate plus ionomycin stimulated versus non-stimulated
mesenchymal stromal cells
The analysis of the protein expression of CD13, CD44,
CD73, CD90, CD106, and CD184 (CXCR4) by flow cy-
tometry showed no differences with biological signifi-
cance for these molecules (data not shown), although
there were significant statistical differences for CD106
(MFI of 2,499 ± 861 and 2,713 ± 869 for non-stimulated
and stimulated MSCs, respectively) and CD184 (MFI of
7,103 ± 2,059 and 8,116 ± 2,224 for non-stimulated and
stimulated MSCs, respectively). In turn, MSCs stimulation
with PMA plus ionomycin induced the increase of IDO,
ICOSL, IL-1β, IL-8, and TNF-α mRNA levels (P <0.05 for
IL-1β, IL-8, and TNF-α) and showed a tendency to de-
crease TGF-β mRNA (not statistically significant), as illus-
trated in Figure 7.Discussion
Despite the increasing number of studies on MSC-derived
immunosuppression of T cells, those which investigated
whether MSCs action differed among T-cell functional
compartments are scarce. As the immune system dis-
order candidates to MSCs cell therapy comprise a het-
erogeneous group concerning the distribution of T cells
among their functional compartments and the effector
T cells underlying the disease, it becomes urgent to
understand how MSCs regulate the distinct T-cell func-
tional compartments.
Thus, in the present study, the influence of MSCs in
the cytokine expression profile of naive, CM, EM, and
effector compartments of CD4+ and CD8+ T cells was
evaluated directly in these subsets naturally occurring in
the peripheral blood of healthy individuals. The above-
mentioned functional compartments were identified
within CD4+ and CD8+ T-cell populations by flow cy-
tometry on the basis of their differential expression of
CD45RA and CD27. The production of IL-2, TNF-α,
and IFNγ was further evaluated within each cell com-
partment. To the best of our knowledge, this is the first
study reporting the effect of MSCs on the cytokine ex-
pression by T cells that analyzed simultaneously all four
functional compartments of CD4+ and CD8+ T cells nat-
urally occurring in the peripheral blood.
Our results showed that, in a co-culture system with
MNCs stimulated with PMA + ionomycin, MSCs down-
regulate TNF-α, IFNγ, and IL-2 protein expression in
both CD4+ and CD8+ T cells, which corroborates previ-
ous studies reporting that MSCs induce the decrease of
these cytokines detected in the co-culture medium
[22,25-30] or at the mRNA level [11,21,22] or the de-
crease of the percentage of T cells producing cytokines
[14,20,29,31,32] in in vitro experiments and in in vivo
animal experimental models [18,19,33].
The analysis of the expression of those pro-inflammatory
cytokines within each T-cell functional compartment re-
vealed that MSCs have the ability to modulate the func-
tion of T cells included in naive, CM, EM, and effector
compartments but to a different extent. Interestingly, ef-
fector CD8+ T cells, which present the highest percentage
of TNF-α-producing cells among CD4+ and CD8+ T-cell
functional compartments, correspond to those which are
less sensitive to MSC-mediated TNF-α downregulation.
Therefore, as TNF-α constitutes an important effector
mechanism of CD8+ T cell-mediated immune response,
with a pivotal role in the pathophysiology of several auto-
immune disorders and graft-versus-host disease, we may
postulate that MSCs present a milder inhibition on cells
with a higher degree of differentiation. Conversely, IL-2
expression is highly inhibited in CM, EM, and effector
CD4+ T cells. MSC-mediated IL-2 downregulation had
already been described for CD4+ or total T cells and is
Figure 4 Percentage of CD4+ and CD8+ T cells expressing interleukin-17 (IL-17). The left upper panels show the percentage (mean ± standard
deviation) of CD4+ and CD8+ T cells producing IL-17 (within total CD4+ T cells and total CD8+ T cells, respectively) and amount of protein expressed
per cell, measured as mean fluorescence intensity (MFI) (mean ± standard deviation), after mononuclear cell (MNC) stimulation with phorbol
myristate acetate (PMA) plus ionomycin in the absence of mesenchymal stromal cells (MSCs) (MNCs + PMA + ionomycin) or in co-culture with
MSCs (MSCs + MNCs + PMA + ionomycin). The right upper panels show the percentage (mean ± standard deviation) of CD4+ and CD8+ T cells
producing simultaneously IL-17 and tumor necrosis factor-alpha (TNF-α) (within IL-17+CD4+ T cells and IL-17+CD8+ T cells, respectively) and
amount of protein expressed per cell, measured as MFI (MFI, mean ± standard deviation), after MNC stimulation with PMA plus ionomycin in
the absence of MSCs (MNCs + PMA + ionomycin) or in co-culture with MSCs (MSCs + MNCs + PMA + ionomycin). The lower panel represents the
percentage of inhibition induced by MSCs on the percentage of CD4+ and CD8+ T cells expressing IL-17 or IL-17 and TNF-α. Statistically significant
differences were considered when P <0.05 for Wilcoxon paired-sample test: *versus MSCs +MNCs + PMA+ ionomycin. CM, central memory; EM,
effector memory.
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[11,21,28]. Similarly to Aggarwal et al. [26], who re-
ported MSC-mediated inhibition of IFNγ in humanCD45RA+ T cells, we observed a decreased frequency
of naive T cells producing IFNγ, but only among CD8+
T cells, whereas no inhibitory effect was detected over
Figure 5 Percentage of CD4+ and CD8+ T cells expressing interleukin-6 (IL-6) or IL-9. The upper panel shows the percentage (mean ± standard
deviation) of CD4+ T cells expressing IL-6 (within total CD4+ T cells) and of total, CD4+, and CD8+ T cells producing IL-9 (within total T cells, CD4+ T cells,
and total CD8+ T cells, respectively), after mononuclear cell (MNC) stimulation with phorbol myristate acetate (PMA) plus ionomycin in the absence of
mesenchymal stromal cells (MSCs) (MNCs + PMA+ ionomycin) or in co-culture with MSCs (MSCs +MNCs + PMA + ionomycin). The lower panel shows
the percentage of inhibition induced by MSCs on the percentage of total, CD4+ and/or CD8+ T cells expressing IL-6 or IL-9. Statistically significant
differences were considered when P <0.05 for Wilcoxon paired-sample test: *versus MSCs +MNCs + PMA+ ionomycin.
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inhibitory effect was observed among the CM, EM, and
effector compartments, compared with naive cells, for
CD4+ and CD8+ T cells; similarly, Krampera et al. [32]
found a stronger inhibitory effect over mouse memory T
cells, compared with naive T cells. In the same line, more
recent studies showed that MSCs induced human me-
mory T cells, whose identification was based on CD45RO
expression, to express IL-17, which did not occur in the
naive compartment [21,23]. At this point, our results and
previously published data support the idea that MSCs dif-
ferently regulate the distinct T-cell functional compart-
ments, which can impact the outcome of MSC therapy.
Concerning other pro-inflammatory cytokines, MSCs
induced a decreased percentage of CD4+ and CD8+ T
cells expressing IL-17 and IL-9 and of CD4+ T cells produ-
cing IL-6. Conversely, at the mRNA level, we observed a
tendency to an increase of the anti-inflammatory IL-4
and TGF-β in CD4+ T cells, as described by others
[1,18,26,29]. The ability to inhibit Th17 differentiation
from mouse and human T cells has been attributed toMSCs, and the ability to decrease the expression of IL-17
in differentiated Th17 is an effect assigned to prostaglan-
din E2 [14-16,19,33,34]; however, the effect of MSCs on T
cells expressing IL-17 is controversial, and some studies
showed that Th17 function can be enhanced by MSCs
[14,20-23]. Nevertheless, the different experimental ap-
proaches used may explain the conflicting data. Beyond
the direct impairment of Th1 and Th17 immune re-
sponses, by reducing the expression of their typical
effector cytokines (TNF-α, IFNγ, IL-2, and IL-17), MSCs
can also induce the expression of the anti-inflammatory
cytokine IL-10 in both Th1 and Th17 cells [16,35].
IL-6 is a cytokine with recognized pro- and anti-
inflammatory properties. Roughly, anti-inflammatory
biological effects can be ascribed to IL-6 classic signal-
ing via membrane IL-6 receptor (IL-6R), whereas pro-
inflammatory function is associated with trans-signaling
mediated by soluble IL-6R (sIL-6R) [36]. The essential role
of this cytokine in inflammation was confirmed by several
animal models of autoimmune inflammatory diseases,
where the blockage of IL-6 trans-signaling prevented the
Figure 6 mRNA expression of interleukin-10 (IL-10), transforming
growth factor-beta (TGF-β), IL-2, IL-4, and CTLA-4 in CD4+ and
CD8+ T cells. The figure shows the results of a semi-quantitative
analysis of IL-10, TGF-β, IL-2, IL-4, and CTLA-4 (cytotoxic T-lymphocyte-
associated protein 4) mRNA expression in fluorescence-activated cell
sorting (FACS)-purified CD4+ and CD8+ T cells from the following
culture conditions: non-stimulated mononuclear cells (MNCs),
non-stimulated MNCs co-cultured with mesenchymal stromal cells
(MSCs) (MNCs + MSCs), MNCs stimulated with phorbol myristate
acetate (PMA) plus ionomycin (MNCs + PMA + ionomycin), and
MNCs stimulated with PMA plus ionomycin in co-culture with
MSCs (MNCs + MSCs + PMA + ionomycin). Statistically significant
differences were considered when P <0.05 for Wilcoxon paired-sample
test, comparing MNCs + PMA + ionomycin versus MNCs + MSCs +
PMA + ionomycin.
Figure 7 mRNA expression of TNF-α, IL-8, IL-1β, TGF-β, ICOSL,
and IDO in MSCs. Semi-quantitative analysis of TNF-α, IL-8, IL-1β,
TGF-β, ICOSL, IDO mRNA expression in non-stimulated MSCs (MSCs)
and in MSCs stimulated with PMA plus ionomycin (MSCs + PMA +
ionomycin). Statistically significant differences were considered when
P <0.05 for Wilcoxon paired-sample test, comparing MSCs versus
MSCs + PMA + ionomycin. ICOSL, inducible costimulatory ligand; IDO,
indoleamine-2,3-dioxygenase; IL, interleukin; MSC, mesenchymal
stromal cell; PMA, phorbol myristate acetate; TGF-β, transforming
growth factor-beta; TNF-α, tumor necrosis factor-alpha.
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ute to proteolytic cleavage of IL-6R, resulting in the re-
lease of sIL-6R, trans-signaling is likely to be enhanced
under this condition; besides, IL-6 is necessary for Th17
differentiation and maintenance [37]. MSC-mediated
reduction of IL-6 expression in CD4+ T cells is in agree-
ment with the decreased expression of the other pro-
inflammatory cytokines evaluated in the present study,
namely the percentage of T cells producing IL-17.
The biological effects of IL-9 are still poorly described.
This cytokine is produced by Th9, Th2, Treg, and Th17
cell subsets and plays an important role in the immune
response against helminthes and in allergic inflammation
[38-40]. Despite promoting Th2 cytokine production,
enhancing the regulatory function of Treg and suppress-
ing the expression of the pro-inflammatory cytokines
TNF-α, IL-12, and IFNγ under certain experimental con-
ditions, IL-9 is also able to expand Th17 cell population
and to promote inflammation, as the adoptive transfer of
Th9-polarized cells induces experimental autoimmune
encephalomyelitis and experimental autoimmune uveitis
[38,41]. Recent works showed that in vivo systemic admin-
istration of MSCs are beneficial in allergic airway inflam-
mation mouse models by increasing IL-10 and decreasing
IL-4, IL-5, and IL-13 cytokine secretion [42-45]. To the
best of our knowledge, IL-9 had never been evaluated in
in vivo MSC-mediated suppression of allergic inflamma-
tion in animal models; also, this is the first study reporting
the inhibition of IL-9-producing CD4+ and CD8+ T cells
by MSCs, opening new possibilities in the investigation of
MSCs in allergic inflammation.Conclusions
MSCs constitute a possible therapeutic approach for
immune-mediated disorders; however, these pathologies
are very heterogeneous in what concerns the effector
T-cell subset involved and the distribution of T cells
among their functional compartments. Thus, a detailed
knowledge of the effect of MSCs over each individual
functional compartment of CD4+ and CD8+ T cells be-
came essential to predict and understand their outcome
as cell therapy. Here, we investigated whether human
BM-MSCs altered the expression of pro-inflammatory
cytokines among the CD4+ and CD8+ T-cell functional
compartments naturally occurring in the peripheral blood.
Overall, our results showed that MSCs inhibit TNF-α,
IFNγ, and IL-2 protein expression in all CD4+ and CD8+
T-cell functional compartments, except for IFNγ expres-
sion in naive CD4+ T cells, where MSCs had no suppres-
sive effect. Interestingly, MSC-derived inhibition was
stronger for CD4+ than CD8+ T cells, concerning IL-2
and TNF-α, but was more pronounced in CD8+ T cells
for IFNγ.
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patterns for the different functional compartments of T
cells. MSC-derived inhibition of TNF-α expression was
more marked among naive, CM, and EM T cells for both
CD4+ and CD8+ T-cell subsets; CM CD4+ T cells and
effector and EM CD8+ T cells were the functional com-
partments displaying a higher degree of suppression of
IFNγ expression; and the inhibition of IL-2 production
was more pronounced among effector, EM, and CM
CD4+ T cells and CM CD8+ T cells.
Finally, we verified that, under our experimental con-
ditions, MSC co-culture reduced the percentage of both
CD4+ and CD8+ T cells expressing IL-17 and IL-9 and
of CD4+ T cells producing IL-6. The influence of MSCs
on IL-9 can open new possibilities of research regarding
the clinical use of MSCs in allergic inflammation.
In the present study, we showed that MSCs differen-
tially regulate the functional compartments of T cells.
Also, the pattern of inhibition of the functional compar-
tments of CD4+ T cells differed from that observed in
CD8+ T cells. Our data revealed that the distinctive distri-
bution of T cells among activation/differentiation com-
partments of immune system disorders will condition the
therapeutic effect of MSCs.
Additional file
Additional file 1: Figure S1. Gating strategy for identifying CD4+ and
CD8+ T cells’ functional compartments and cytokine expression among
each T-cell compartment. Bivariate dot plot histograms illustrate (A-C)
overall T cells in the cell culture and (C) CD4+ (blue events) and CD8+
(pink events) T cells. The identification of T cells’ functional compartments
was made within CD8+ (D) and CD4+ (E) T-cell subpopulations, based on
CD45RA and CD27 expression, as follows: CD45RA+CD27+ phenotype
corresponds to naive (N) T cells, CD45RA−CD27+ corresponds to central
memory (CM), effector memory (EM) T cells are CD45RA−CD27−, and
effector (E) T cells display CD45RA+CD27− phenotype. The expression of
cytokines—illustrated in (F) for CD8+ T cells and in (G) for CD4+ T cells—
was evaluated within each CD4+ and CD8+ T-cell functional compartment.
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